EU regulator reviewing possible links between Johnson & Johnson jab and blood clots

World

Europe’s drugs regulator is reviewing possible links between blood clots and Johnson & Johnson’s coronavirus vaccine.

It comes after four serious cases of rare clots with low platelets were reported after inoculation, one of which was fatal, according to the European Medicines Agency (EMA).

The Johnson & Johnson (also known as Janssen) vaccine has been rolled out in the European Union and the US in recent months, having proved 67% effective in preventing COVID-19 and completely effective at preventing hospital admissions and death from the virus during trials.

It stands out from the other jabs being used because only one shot is needed, rather than two.

The UK has ordered 30 million doses, but it has not yet been approved by the regulator.

Both the EMA and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) have investigated links between rare clots and the Oxford-AstraZeneca vaccine, but this is the first formal disclosure that the Janssen jab is also being looked into.

Products You May Like

Articles You May Like

Biden calls on Congress to suspend the gas tax — Here’s what that means for prices at the pump
UiPath to cut 5% of its workforce as part of restructuring plan
‘Back together’: Paul McCartney and John Lennon reunited at Glastonbury Festival
Intel warns Ohio factory could be delayed because Congress is dragging its feet on funding
Where do G7 countries like the US, Japan, and Germany stand in their shift to clean energy?

Leave a Reply

Your email address will not be published.